Heart Test Laboratories, Inc. P/EBITDA LTM
| Apr'23 | Apr'24 | |
|---|---|---|
| P/EBITDA LTM | (1.4x) | (1.1x) |
Heart Test Laboratories, Inc. (HSCS) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
HSCS key stats
| Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|
% growth | 0.1 0.0% | 0.0 (60.1%) | 0.0 (43.9%) | 0.0 (64.2%) | 0.0 261.2% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 27.6% | 0.0 58.3% | 0.0 45.1% | 0.0 45.7% | 0.0 67.3% |
| Operating Expenses | 3.8 | 2.6 | 4.7 | 6.1 | 6.3 |
| Research & Development Expenses (R&D) | 2.0 | 1.7 | 3.0 | 2.5 | 2.9 |
| Selling, General & Administrative Expenses (SG&A) | 1.8 | 0.9 | 1.7 | 3.7 | 3.4 |
% margin | (3.8) (5,949.0%) | (2.6) (10,030.2%) | (4.7) (32,765.6%) | (6.1) (118,698.3%) | (6.3) (33,902.0%) |
| Interest Income | 0.0 | 0.1 | 0.4 | 0.2 | 0.0 |
| Interest Expense | 0.0 | 0.1 | 0.4 | 0.2 | 0.4 |
| Pre-tax Income | (3.8) | (2.5) | (4.8) | (6.4) | (6.6) |
% effective tax rate | 0.0 (0.6%) | 0.1 (5.3%) | (0.3) 5.2% | 484.5 (7,624.8%) | 0.0 0.0% |
% margin | (3.8) (5,973.4%) | (2.6) (10,081.1%) | (4.6) (31,851.8%) | (490.9) (9,531,151.3%) | (6.6) (35,511.9%) |
| EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
| Diluted EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
% margin | (3.7) (5,834.2%) | (2.3) (8,928.7%) | (4.4) (30,822.2%) | (6.1) (118,139.8%) | (6.2) (33,096.7%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Heart Test Laboratories, Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is (424.4x), based on the financial report for Oct 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for Heart Test Laboratories, Inc. have been (29.3x) over the past three years, and (22.0x) over the past five years.
2) Is Heart Test Laboratories, Inc.'s P/EBITDA LTM Good?
As of today, Heart Test Laboratories, Inc.'s P/EBITDA LTM is (424.4x), which is lower than industry median of (0.9x). It indicates that Heart Test Laboratories, Inc.'s P/EBITDA LTM is Good.